Today: 9 April 2026
Idox share price sits just under 71.5p bid as takeover backer flags 49% support
7 February 2026
2 mins read

Idox share price sits just under 71.5p bid as takeover backer flags 49% support

London, Feb 7, 2026, 09:02 GMT — The market is closed.

  • Idox wrapped up Friday at 71.0 pence, gaining 0.3%. That’s just shy of the 71.5p cash offer.
  • Bidder disclosures reflected almost 50% total backing through a mix of undertakings, letters of intent, and their current holding, with valid acceptances accounting for another 19%.
  • March 16 marks the next key date, as the offer hits “Day 60” on the timetable.

Idox finished Friday at 71.0 pence, inching up 0.28%. The stock ticked higher as the suitor for its 71.5 pence-per-share cash bid revealed new endorsements from shareholders along with some early acceptances. Hargreaves Lansdown

Those numbers have real weight at this stage—with the deal not yet unconditional, Frankel UK Bidco still needs to secure more than 50% of voting rights under UK takeover rules. Day to day, the market is pricing in how likely that outcome is.

Idox, the AIM-listed software firm, has sat in “offer period” mode ever since last year’s bid came out. On Monday, attention turns to that tight spread between the share price and the offer—plus any shift as holders convert promises into actual signed acceptances.

Frankel reported that irrevocable undertakings and non-binding letters of intent now account for 170.5 million shares, roughly 36.93% of Idox’s issued share capital, while Long Path’s 12.32% stake brings “aggregate support” to about 49.26%. The latest figures reflect a shifting landscape: some investors pared back after selling shares, but others have increased their stated holdings. investegate.co.uk

The separate “day 21” update logged valid acceptances for 88.3 million shares—19.12%—as of 4:30 p.m. London time on Feb. 5. Frankel at that stage said roughly 25.34% could be counted toward the acceptance condition. He’s holding firm: the offer hinges on gaining control of over 50% of Idox’s voting rights. The bid is set to close at 1 p.m. London time on March 16 unless it’s extended. Frankel also repeated that if they hit 75% after the offer goes unconditional, Idox shares would be delisted from AIM. Hit 90%, and a compulsory acquisition of the remainder is on the table. investegate.co.uk

Idox wrapped up the week trading just under the cash offer by about half a penny—a minor discount that typically signals timing or paperwork risk, plus a faint chance the deal falls through or gets tweaked. Friday saw brisk volumes, highlighting how closely Idox shares are hugging the bid.

More dealings surfaced. Peel Hunt, acting as Idox’s joint adviser and broker, logged client trades on Feb. 5: 76,051 shares bought, 21,887 sold, according to a Takeover Code Form 8.5 disclosure. Halifax Investments

Octopus Investments, which holds roughly 14.60% of Idox, said it sold 137,668 shares at 70.85 pence, according to a Form 8.3 filed Feb. 6. GlobeNewswire

Still, headline support numbers can mislead. Letters of intent? Not binding. Even those so-called “irrevocable” commitments often include outs if a rival bid comes in higher. And as of day 21, the acceptance count hadn’t reached a majority.

This week looks set to be a slow trickle—fresh acceptance updates, more disclosures under the Takeover Code, and the usual scan for clues on whether Frankel is edging closer to its target threshold. Mark March 16: that’s day 60 on the offer clock, and it’s the one solid date to watch.

Stock Market Today

  • Sumitomo Pharma's New Shares and Secondary Offering Could Shift Investment Outlook
    April 9, 2026, 4:32 AM EDT. Sumitomo Pharma (TSE:4506) plans a new share issuance combined with a secondary offering, potentially altering ownership and per-share economics. The initiative comes after a recent guidance upgrade, projecting increased revenue and net profit by fiscal 2026 thanks to stronger sales and currency effects. Despite this, the offering does not change the core risks: high debt levels and reliance on one-off gains. Analysts remain divided, with some forecasting more optimistic earnings growth while others caution on sustainability. The company projects modest revenue growth to 2029, with earnings expected to decline from current levels. This share move introduces new tension between near-term earnings support and balance sheet pressure as the company advances regenerative therapies and North American projects. Investors should weigh revised forecasts and changing capital structure carefully.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 4:38 AM EDT Sumitomo Pharma's New Shares and Secondary Offering Could Shift Investment Outlook April 9, 2026, 4:32 AM EDT. Sumitomo Pharma (TSE:4506) plans a new share issuance combined with a secondary offering, potentially altering ownership and per-share economics. The initiative comes after a recent guidance upgrade, projecting increased revenue and net profit by fiscal 2026 thanks to stronger sales and currency effects. Despite this, the offering does not change the core risks: high debt levels and reliance on one-off gains. Analysts remain divided, with some forecasting more
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Barclays share price jumps into earnings week as BoE rate-cut bets shift the story
Previous Story

Barclays share price jumps into earnings week as BoE rate-cut bets shift the story

BAE Systems share price rises into weekend — what to watch before Monday’s London open
Next Story

BAE Systems share price rises into weekend — what to watch before Monday’s London open

Go toTop